13 Feb 2018

Press Release: Next Frontier Biosciences Assembles Distinguished Research and Development Team

Press Release: Next Frontier Biosciences Assembles  Distinguished Research and Development Team


Next Frontier Biosciences Assembles

Distinguished Research and Development Team


Biotech company draws upon highly experienced scientists and researchers

to develop and commercialize best-in-class cannabis products


DENVER (February 13, 2018) – Colorado-based biotech company Next Frontier Biosciences today announced the assembly of its Research and Development Team, enhancing the company’s lineup of accomplished biotechnology executives and research scientists. After successfully launching its first generation Verra Wellness line of products in the Colorado adult-use and medical marijuana markets in November, the company is seeking to expand into emerging cannabis markets, both domestically and internationally, and plans to introduce at least two new products in 2018.


“Our Research and Development Team plays an integral role in creating new products and supporting our expansion strategy, including developing robust manufacturing processes, product specifications, and standard operating procedures” said Marc Graboyes, Co-Founder and CEO of Next Frontier Biosciences. “In turn, their work allows us to pursue valuable intellectual property rights and implement a broad-based licensing program wherein our proprietary formulations and brands are made available to third parties who possess the licenses and facilities required to manufacture, sell and distribute our best-in-class cannabis products in their respective markets.”


Leading the team is Paul Johnson, Ph.D., Co-Founder and Chief Scientific Officer of Next Frontier Biosciences. “This group of bright, accomplished scientists and researchers is a major asset to Next Frontier and its Verra Wellness brand, fueling the continued growth of our product pipeline and propelling us into new emerging markets,” Dr. Johnson said.



Dr. Johnson has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and has authored or invented over 100 patents and scientific publications. Dr. Johnson has substantial experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.



Dorothy “Dot” Colagiovanni, Ph.D. serves as Vice President of Product Development at Next Frontier Biosciences, where she is responsible for the day-to-day management of Next Frontier’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne. She also held research positions with OSI Pharma, Gilead Sciences and Amgen. Dr. Colagiovanni has a broad range of development experience, starting from early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen Boulder.


“Our ultimate objective is to make the benefits of cannabis more widely available through discreet, smoke-free delivery technologies. The desire to bring healthier and safer alternatives to the market is the common thread uniting our team and motivating our efforts in the lab every day,” Dr. Colagiovanni said. “Each member brings a unique area of expertise to the table, which lends itself to continued innovation–supporting our overarching goal at Next Frontier Biosciences.”


Stephen Cape, Ph.D., is Next Frontier’s Director of Formulation Sciences. Dr. Cape has more than 15 years of experience developing formulations of pharmaceuticals, biologicals and vaccines for alternative routes of delivery, including sublingual, nasal, transdermal and inhalation. Prior to joining Next Frontier, he held technical and project leadership roles at the University of Colorado and Aktiv-Dry LLC (Boulder, CO). Dr. Cape led the formulation and spray-drying process development of the first inhaled dry powder measles vaccine to successfully complete a Phase I clinical trial. He has broad experience in early-stage basic R&D, formulation and process development, and technology transfer for GMP manufacturing.


“It’s an exciting time to work in the emerging cannabis space, and our team is advancing Next Frontier Biosciences to the forefront of the cutting-edge research and development that will elevate the industry to a higher standard of scientific excellence,” Dr. Cape said. “The work we contribute in the lab will yield a positive, tangible impact as consumers find more consistent and reliable options with the comfort and flexibility to select their preferred method of administration.”


Kris Chupka, Next Frontier’s Director of Analytical Chemistry brings to the team over 18 years of research and development analytical experience from the electronics and pharmaceutical industries. His specialties are chromatographic separations, mass spectrometry and thermal mechanical analysis. Prior to joining Next Frontier Biosciences, Mr. Chupka held analytical chemistry leadership roles for Atotech, Novartis, Mylan and Western Digital. He has a proven track record in supportive analytical development from conceptual research and development to commercial product support.


“Our analytical capabilities–including a high resolution mass spectrometer–provide us with the ability to fully characterize all aspects of Next Frontier Biosciences products, from flower to filled device,” Mr. Chupka said. “Consumers can rest assured knowing that the Next Frontier Biosciences name represents a profound commitment to sophisticated, well-characterized products that are unmatched in quality.”



Susan Schwarz serves as Senior Analytical Chemist at Next Frontier Biosciences. Ms. Schwarz is a biotechnology professional with extensive experience in all stages of biopharmaceutical development from drug discovery to cGMP manufacturing. She has utilized numerous types of analytical instrumentation throughout her career. Ms. Schwarz has held positions from Quality Control Chemist (Somatogen) working with recombinant hemoglobin to Analytical Chemist (Takeda Vaccines) for process scale up (from 1L to 50L) and tech transfer of a norovirus vaccine using single-use technology to a contract manufacturing organization.


“The scalable process that results from our Research and Development team will serve to support our technology transfer and licensing program, ensuring that the Verra Wellness suite of purified cannabinoid-infused products can reach new demographics in new regions,” Ms. Schwarz said.



The newest member of the research team, Andres Gandara, joins as Formulation Scientist. A graduate of the University of Colorado with a bachelor’s degree in Chemical Engineering, Mr. Gandara comes to Next Frontier Biosciences with a strong engineering and business background, having previously worked at Bayer CropScience in Guatemala, Transform Energy in Golden, and most recently at Custom Solar in Boulder.


“Next Frontier Biosciences is a proven leader in product innovation. Participating in the rigorous formulation process from beginning to end–all while playing an active role in bringing novel and effective cannabinoid-infused products to new markets–is extremely rewarding,” Mr. Gandara said.


Founded in 2014, Next Frontier Biosciences has assembled a team of highly experienced biotech executives and research scientists with over 120 years of pharmaceutical drug development experience. The company employs a traditional scientific approach to product development that includes advanced purification, analytical and chemical formulation methods. Next Frontier Biosciences’ proprietary formulations were carefully developed and optimized for improved delivery via nasal, sublingual and topical administration with a focus on providing unparalleled quality, consistency and reproducibility.


For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or shawna@rosengrouppr.com.


About Next Frontier Biosciences: At Next Frontier Biosciences, we believe that cannabinoid purification and scientific formulation are the keys to unlocking the power of the plant and developing safer and more effective cannabinoid-based products. Scientifically formulated to provide accurate dosing, improved bioavailability and optimized cannabinoid profiles, our Verra Wellness line of products, including nasal mists, sublingual sprays and topical salves, offer fast acting and consistent results. Additionally, their unique modes of administration are discreet and effective, providing both medical and adult-use cannabis consumers with desirable alternatives to smoking, vaporizing or eating cannabis-infused products. At Next Frontier Biosciences, we maintain an unyielding commitment to scientific excellence and integrity, so our products aren’t just created from cannabis—they’re derived from truth.


For more information, visit http://nextfrontierbio.com/. Follow us on Facebook, Twitter, Instagram and LinkedIn.



# # #

05 Feb 2018

Dr. Dot Colagiovanni Featured on This Week’s Cannabis Economy Podcast

Dr. Dot Colagiovanni Featured on This Week’s Cannabis Economy Podcast

Next Frontier’s Vice President of Product Development, Dr. Dot Colagiovanni was interviewed for this week’s Cannabis Economy podcast, hosted by Seth Adler.


A summary of the segment is provided below, and the full interview is available on the Cannabis Economy website: http://www.canneconomy.com 


Dr. Dot Colagiovanni joins us and shares that she’s got a PhD in toxicology, which she put to use in the biotech industry for 20 years until she became disillusioned with the FDA working slowly but also hedge funds coming in to biotech and driving decision making as opposed to the science. She wanted to bring medicine to market sooner at the same time as her son had to have a liver transplant. During the wait to find a liver, Dot wanted to be present and so she and she alone self medicated with cannabis after her son went to bed. She had never utilized cannabis medically and she says, cannabis helped her cope. She put two and two together and realized the cannabis industry was where she needed to be.


Hosted by Seth Adler, Cannabis Economy is a real-time history of legal cannabis. We chronicle how personal and industry histories have combined to provide our current reality. Who you are informs what you do. Business is personal.

16 Jan 2018

CFN Media Interviews Next Frontier Biosciences

CFN Media Interviews Next Frontier Biosciences

Research and development into medicinal cannabis has grown by leaps and bounds since the rise of legalization. Next Frontier Biosciences is a biotech firm specializing in the creation of best-in-class purified cannabinoid products specifically designed for the medical markets. Using advanced formulation sciences, the company has already introduced a line of sublinguals, nasal mists, and topicals to the cannabis industry. The Verra Wellness line of products is meant to help new consumers ease into cannabis consumption.


CFN Media recently sat down with Next Frontier Co-Founder and CEO, Marc Graboyes, and Vice President, Pharmaceutical Development, Dorothy “Dot” Colagiovanni, Ph.D. , to learn more about the company’s impressive scientific and research-based approach to cannabis product development.


Rachelle Gordon: What is the history of Next Frontier Biosciences?


Marc Graboyes: Myself, along with my partner Paul Johnson, came together to bring advanced sciences to the cannabis industry; we recruited Dot a short time later before we founded Next Frontier in late 2014. We’ve been actively pursuing formulation sciences and product development for the last two and half years to the point where we are now launching our first line of branded products in Colorado this week.


The name of the line is Verra Wellness, which offers purified cannabinoid products for nasal, sublingual, and topical delivery. We’re really excited to launch in Colorado, and then we’ll be pursuing a multi-state expansion strategy with the goal of licensing our propriety formulations and brand identity in multiple states with a focus on California, Oregon, Washington and Nevada.


We are a group of former biotech executives and research scientists who are bringing advanced formulation sciences to the cannabis industry, working with highly purified cannabinoids and scientifically formulating them for improved delivery. We also are an IP holding company and provide brand management.


RG: What is the benefit of Verra Wellness for the end user?


MG: It’s really the fact that the Verra Wellness purified cannabinoid products are so accurate, consistent, and convenient for microdosing, which allows you to achieve the maximum benefit with the minimum dose. We are providing alternative modes of administration for people who don’t want to smoke, vaporize, or eat cannabis products and we like think the products are kind of sexy. They look great, they’re very convenient, and discreet. If you have a soccer mom that just wants to throw a discreet container in her purse that’s pretty easy to do and doesn’t have that sort of stigma associated with smoking or vaporizing.


Dot Colagiovanni: Our tag line is Derived From Truth. The word Verra comes from the French word meaning derived from truth; this is who we are philosophically. We’re coming to this industry trying to be transparent, and upfront with what we’re doing, all while providing really good science and hard data to take the industry to the next level of that credibility.


RG: What else sets Next Frontier apart from potential competitors?


DC: First of all, we’ve developed consistent, reliable, and safe products that we think will benefit consumers. We didn’t come into it like a lot of people do having already been in the industry or come into it from business standpoint. We took a different approach: coming from the science side of it. We felt that’s where our strength is and we all know how to develop drugs; the difference between making a cannabis product and making a pharmaceutical product isn’t that big. Our team has the expertise.


MG: Another thing that really sets us apart is our target audience/market. We’re not going after the traditional cannabis consumer who is simply looking to “get high.” We’re looking to provide much more of a therapeutic wellness benefit, whether it’s on the recreational or medical side. We like to target those who were previously scared by the stigma of cannabis, making it a lot more approachable while providing great branding where people would be excited and proud to be carrying our products with them. We are trying to bring new people into the market.

See the full interview on the CannabisFN website.

11 Jan 2018

5280: Denver’s Digital Health Boom

5280: Denver’s Digital Health Boom

The latest issue of 5280 Magazine features Colorado marijuana companies harnessing cutting-edge tech to deliver more personalized treatment to patients all over the world–and Next Frontier Biosciences was included! View the feature below and on the 5280 website.


The Problem: Inconsistent doses of MJ

The Solution: Some Coloradans consume marijuana as a substitute for antidepressants. It’s called “microdosing”—taking 0.3 to just under five milligrams as opposed to the state-recommended dose of 10 milligrams for recreational use. The issue, whether you smoke or eat the pot, is measuring out a consistent dose. Not only do Next Frontier scientists engineer marijuana that delivers the same level of THC every time, but the Denver company’s Verra Wellness brand also packages the cannabis in nasal mist and sublingual (under the tongue) spray canisters. Both of those areas absorb THC quickly, ensuring you don’t overindulge due to a delayed response.

10 Jan 2018

Cannabis Business Executive: 2017 Recap and New Year’s Wishes from Cannabis Industry Leaders

To kick off the new year, Cannabis Business Executive asked several cannabis industry pioneers and leaders to share their wishes and predictions for the industry in 2018. Marc Graboyes, Co-Founder and CEO of Next Frontier Biosciences was among those featured in the article.


His predictions and wishes for 2018 are below:


“For 2018, I’m excited to see the cannabis industry continue embracing the power of scientific research and development to develop safer and more effective cannabinoid based products. I expect the industry to more deeply explore the benefits of cannabinoid purification and scientific formulation in the quest for cleaner and more well-characterized products that are free from the harmful effects associated with smoking. As we educate the public about the therapeutic benefits of cannabinoids, we will see patients trading in their dangerous opioids for safer cannabinoid-based products. With these improvements, the health and wellness communities will take notice of the important work the cannabis industry is doing, allowing us to expand our reach and spread the word to more individuals about how cannabis-based products can help improve their lives.


In the coming year, we will see the industry place a stronger emphasis on research, promoting a scientific evidence-based approach that will allow us to learn more about the vast potential of the plant. Contributing to the growing body of literature on cannabis will help us build and expand upon our current knowledge while informing our future efforts. As an industry, we will continue advocating for sensible legislation so that we can turn back the damage wreaked by prohibition and eventually overcome the negative stigma surrounding cannabis altogether. In turn, we will foster an academic dialogue that elevates the industry to the highest standards of excellence and cultivate a positive nationwide discourse.”


To read the full article, visit Cannabis Business Executive.

03 Jan 2018

Dr. Dot Colagiovanni Named Among Top Ten Influential Women to Meet at the NCIA Seed to Sale Show

Dr. Dot Colagiovanni Named Among Top Ten Influential Women to Meet at the NCIA Seed to Sale Show

Congratulations to Next Frontier’s Vice President of Pharmaceutical Development, Dr. Dot Colagiovanni, who has been named one of the top ten most influential women to meet at this year’s NCIA Seed to Sale Show, taking place in Denver on February 7th and 8th.


Dr. Colagiovanni will be presenting at the conference on February 7th from 11:15 am-12:30 pm in a session titled “Controlling Terpenes and Cannabinoids in Flower and Extract.” For more details, visit the 2018 NCIA Seed to Sale Show website.

07 Dec 2017

Cannabis Industry Journal: New Drug Delivery Mechanisms For Cannabis Products

Cannabis Industry Journal: New Drug Delivery Mechanisms For Cannabis Products

Next Frontier Biosciences announced the launch of their new product line, Verra Wellness, in the Colorado market this week. The products are designed with relatively new concepts for the cannabis market, including nasal, sublingual and topical administration.


Co-founded by biotech executives Marc Graboyes and Dr. Paul Johnson, Ph.D, Next Frontier Biosciences is developing this product line with three formulations, each with a different ratio of THC and CBD. According to a press release, Next Frontier Biosciences is focused on developing cannabis products with these new drug delivery methods, and even offering a microdosing option.


“We believe that leveraging science and research is the key to optimizing product development,” says Dr. Johnson, one of the co-founders. “With the introduction of our Verra Wellness line of products, we are reshaping the cannabis industry by offering trusted products that provide uniform composition, formulation and dosing in highly consistent modes of administration.”


Read more about Next Frontier’s novel delivery technologies–including the world’s first cannabis nasal mist–on Cannabis Industry Journal.

06 Dec 2017

Cannabis Business Executive: Next Frontier Biosciences Launches Revolutionary Product Line Verra Wellness

Cannabis Business Executive: Next Frontier Biosciences Launches Revolutionary Product Line Verra Wellness

Next Frontier Biosciences announced today the launch of its Verra Wellness line of purified cannabinoid products into the medical and adult-use marijuana markets in Colorado. The Verra Wellness products are scientifically formulated for improved delivery via nasal, sublingual and topical administration and provide patients and consumers with safe, effective and discreet alternatives to smoking, vaporizing or eating cannabis-infused products. The Verra Wellness offering includes the world’s first cannabis nasal mist. The line also consists of a sublingual spray and a topical salve.


Read more on Cannabis Business Executive.

To learn more about the revolutionary Verra Wellness product line, visit: https://verrawellness.com/